Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance

Authors: Geoffrey Martinage, Angela M. Hong, Mike Fay, Thanuja Thachil, Daniel Roos, Narelle Williams, Serigne Lo, Gerald Fogarty

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

Melanoma brain metastases (MBM) often cause morbidity and mortality for stage IV melanoma patients. An ongoing randomised phase III trial (NCT01503827 – WBRT-Mel) evaluates the role of adjuvant whole brain radiotherapy (WBRT) following local treatment of MBM. Hippocampal avoidance during WBRT (HA-WBRT) has shown memory and neurocognitive function (NCF) preservation in the RTOG-0933 phase II study. This study assessed the quality assurance of HA-WBRT within the WBRT-Mel trial according to RTOG-0933 study criteria.

Methods

Hippocampal avoidance was allowed in approved centres with intensity-modulated radiotherapy capability. Patients treated by HA-WBRT were not randomized within the WBRT arm. The RTOG 0933 contouring Atlas was used to contour hippocampi. In the trial co-ordinating centre, patients were treated with volumetric modulated arc therapy using complementary arcs; similar techniques were used at other sites. Dosimetric data were extracted retrospectively and analysed in accordance with RTOG 0933 study constraints criteria.

Results

Among the 215 patients accrued to the WBRT-Mel study between April 2009 and September 2017, 107 were randomized to the WBRT arm, 22 were treated by HA-WBRT in 4 centers. Eighteen patients were treated in the same centre. The median age was 65 years. The commonest (91%) HA-WBRT schema was 30 Gy in 10 fractions. Prior to HA-WBRT, 10 patients had been treated by surgery alone, six by radiosurgery alone, four by surgery and radiosurgery and two exclusively by simultaneous integrated boost concurrent to HA-WBRT. Twenty patients were treated with intention to spare both hippocampi and two patients had MBM close to one hippocampus and were treated with intention to spare the contralateral hippocampus. According to RTOG-0933 study criteria, 18 patients (82%) were treated within constraints and four patients (18%) had unacceptable deviation in just one hippocampus.

Conclusions

This dosimetric quality assurance study shows good compliance (82%) according to RTOG-0933 study dosimetric constraints. Indeed, all patients respected RTOG hippocampal avoidance constraints on at least one hippocampus. In the futureanalysis of the WBRT-Mel trial, the NCF of patients on the observation arm, WBRT arm and with HA-WBRT arm will be compared.
Literature
1.
Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit Cancer surveillance system. J Clin Oncol. 2004 Jul 15;22(14):2865–72.CrossRefPubMed
2.
3.
Fogarty GB, Hong A, Jacobsen KD, Reisse CH, Shivalingam B, Burmeister B, et al. Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible. BMC Res Notes. 2014;7:412.CrossRefPubMedPubMedCentral
4.
Fogarty GB, Hong A, Dolven-Jacobsen K, Reisse CH, Burmeister B, Haydu LH, et al. First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Res Notes. 2015;8:192.CrossRefPubMedPubMedCentral
5.
Taillibert S, Le Rhun É. Epidemiology of brain metastases. Cancer Radiother J Soc Francaise Radiother Oncol. 2015;19(1):3–9.
6.
Fogarty GB, Hong A, Gondi V, Burmeister B, Jacobsen K, Lo S, et al. Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer. 2016;16:372.CrossRefPubMedPubMedCentral
7.
Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-brain radiotherapy for brain metastases: evolution or revolution? J Clin Oncol Off J Am Soc Clin Oncol. 2017;22:JCO2017759589.
8.
Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases—translation to new therapies. Nat Rev Clin Oncol. 2011;8(6):344–56.CrossRefPubMedPubMedCentral
9.
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–95.CrossRefPubMed
10.
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459–65.CrossRefPubMed
11.
Long GV, Atkinson V, Menzies AM, Lo S, Guminski AD, Brown MP, et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). J Clin Oncol. 2017;35(15_suppl):9508.CrossRef
12.
Tio M, Wang X, Carlino MS, Shivalingam B, Fogarty GB, Guminski AD, et al. Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell Melanoma Res. 2018;31(4):509–15.
13.
Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32(34):3810–6.CrossRefPubMedPubMedCentral
14.
Fogarty G, Morton RL, Vardy J, Nowak AK, Mandel C, Forder PM, et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial. BMC Cancer. 2011;11:142.CrossRefPubMedPubMedCentral
15.
Mizumatsu S, Monje ML, Morhardt DR, Rola R, Palmer TD, Fike JR. Extreme sensitivity of adult neurogenesis to low doses of X-irradiation. Cancer Res. 2003;63(14):4021–7.PubMed
16.
Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian JV, et al. Estimated risk of Perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2010;95(3):327–31.CrossRef
17.
Hong AM, Suo C, Valenzuela M, Haydu LE, Jacobsen KD, Reisse CH, et al. Low incidence of melanoma brain metastasis in the hippocampus. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;111(1):59–62.CrossRef
18.
Sun B, Huang Z, Wu S, Shen G, Cha L, Meng X, et al. Incidence and relapse risk of intracranial metastases within the perihippocampal region in 314 patients with breast cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;118(1):181–6.CrossRef
19.
Wang SJ, Choi M, Fuller CD, Salter BJ, Fuss M. Intensity-modulated radiosurgery for patients with brain metastases: a mature outcomes analysis. Technol Cancer Res Treat. 2007;6(3):161–8.CrossRefPubMed
20.
Lawson JD, Wang J-Z, Nath SK, Rice R, Pawlicki T, Mundt AJ, et al. Intracranial application of IMRT based radiosurgery to treat multiple or large irregular lesions and verification of infra-red frameless localization system. J Neuro-Oncol. 2010;97(1):59–66.CrossRef
21.
Clark GM, Popple RA, Young PE, Fiveash JB. Feasibility of single-isocenter volumetric modulated arc radiosurgery for treatment of multiple brain metastases. Int J Radiat Oncol Biol Phys. 2010;76(1):296–302.CrossRefPubMed
22.
Gondi V, Cui Y, Mehta MP, Manfredi D, Xiao Y, Galvin JM, et al. Real-time pre-treatment review limits unacceptable deviations on a cooperative group radiotherapy technique trial: quality assurance results of RTOG 0933. Int J Radiat Oncol Biol Phys. 2015;91(3):564–70.CrossRefPubMedPubMedCentral
23.
24.
25.
Shen J, Bender E, Yaparpalvi R, Kuo H-C, Basavatia A, Hong L, et al. An efficient volumetric arc therapy treatment planning approach for hippocampal-avoidance whole-brain radiation therapy (HA-WBRT). Med Dosim. 2015;40(3):205–9.CrossRefPubMed
26.
Pokhrel D, Sood S, McClinton C, Shen X, Lominska C, Saleh H, et al. Treatment planning strategy for whole-brain radiotherapy with hippocampal sparing and simultaneous integrated boost for multiple brain metastases using intensity-modulated arc therapy. Med Dosim Off J Am Assoc Med Dosim. 2016;41(4):315–22.
27.
Nevelsky A, Ieumwananonthachai N, Kaidar-Person O, Bar-Deroma R, Nasrallah H, Ben-Yosef R, et al. Hippocampal-sparing whole-brain radiotherapy using Elekta equipment. J Appl Clin Med Phys. 2013;14(3):4205.CrossRefPubMed
28.
Prokic V, Wiedenmann N, Fels F, Schmucker M, Nieder C, Grosu A-L. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013;85(1):264–70.CrossRefPubMed
29.
Pokhrel D, Sood S, Lominska C, Kumar P, Badkul R, Jiang H, et al. Potential for reduced radiation-induced toxicity using intensity-modulated arc therapy for whole-brain radiotherapy with hippocampal sparing. J Appl Clin Med Phys. 2015;16(5):131–41.CrossRefPubMedPubMedCentral
30.
Wang S, Zheng D, Zhang C, Ma R, Bennion NR, Lei Y, et al. Automatic planning on hippocampal avoidance whole-brain radiotherapy. Med Dosim Off J Am Assoc Med Dosim. 2017;42(1):63–8.
31.
Sood S, Pokhrel D, McClinton C, Lominska C, Badkul R, Jiang H, et al. Volumetric-modulated arc therapy (VMAT) for whole brain radiotherapy: not only for hippocampal sparing, but also for reduction of dose to organs at risk. Med Dosim Off J Am Assoc Med Dosim. 2017;42(4):375–83.
32.
Cheah SK, Matthews T, Teh BS. Hippocampal sparing whole brain radiotherapy and integrated simultaneous boost vs stereotactic radiosurgery boost: a comparative Dosimetric planning study. Asian Pac J Cancer Prev APJCP. 2016;17(9):4233–5.PubMed
33.
Farjam R, Pramanik P, Aryal MP, Srinivasan A, Chapman CH, Tsien CI, et al. A radiation-induced hippocampal vascular injury surrogate marker predicts late neurocognitive dysfunction. Int J Radiat Oncol Biol Phys. 2015;93(4):908–15.CrossRefPubMedPubMedCentral
34.
Pospisil P, Kazda T, Bulik M, Dobiaskova M, Burkon P, Hynkova L, et al. Hippocampal proton MR spectroscopy as a novel approach in the assessment of radiation injury and the correlation to neurocognitive function impairment: initial experiences. Radiat Oncol. 2015;10:211. https://​doi.​org/​10.​1186/​s13014-015-0518-1.
35.
Pospisil P, Kazda T, Hynkova L, Bulik M, Dobiaskova M, Burkon P, et al. Post-WBRT cognitive impairment and hippocampal neuronal depletion measured by in vivo metabolic MR spectroscopy: results of prospective investigational study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;122(3):373–9.CrossRef
36.
Kazda T, Vrzal M, Prochazka T, Dvoracek P, Burkon P, Pospisil P, et al. Left hippocampus sparing whole brain radiotherapy (WBRT): a planning study. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov. 2017;161(4):397–402.CrossRef
37.
Lee TMC, Yip JTH, Jones-Gotman M. Memory deficits after resection from left or right anterior temporal lobe in humans: a meta-analytic review. Epilepsia. 2002;43(3):283–91.CrossRefPubMed
38.
Ma TM, Grimm J, McIntyre R, Anderson-Keightly H, Kleinberg LR, Hales RK, et al. A prospective evaluation of hippocampal radiation dose volume effects and memory deficits following cranial irradiation. Radiother Oncol. 2017;125(2):234–40.CrossRefPubMed
39.
Gondi V, Hermann BP, Mehta MP, Tomé WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys. 2013;85(2):348–54.CrossRefPubMed
40.
Tsai P-F, Yang C-C, Chuang C-C, Huang T-Y, Wu Y-M, Pai P-C, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: a prospective study. Radiat Oncol. 2015;10:253
41.
Okoukoni C, McTyre ER, Ayala Peacock DN, Peiffer AM, Strowd R, Cramer C, et al. Hippocampal dose volume histogram predicts Hopkins verbal learning test scores after brain irradiation. Adv Radiat Oncol. 2017;2(4):624–9.CrossRefPubMedPubMedCentral
Metadata
Title
Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance
Authors
Geoffrey Martinage
Angela M. Hong
Mike Fay
Thanuja Thachil
Daniel Roos
Narelle Williams
Serigne Lo
Gerald Fogarty
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-018-1077-z

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue

Research

Proton and helium ion radiotherapy for meningioma tumors: a Monte Carlo-based treatment planning comparison

Research

The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases

Research

Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up

Research

Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma

Research

Predicting patterns of failure in temporal lobe GBMs: possible implications on radiotherapy treatment portals

Case report

Bone marrow suppression as a complication of total skin helical tomotherapy in the treatment of mycosis fungoides